Contineum Therapeutics, Inc. (CTNM) - Cash per Single Share

Symbol and logo of brand Contineum Corp (CTNM)

Contineum Therapeutics, Inc. (CTNM) develops drugs for brain disorders based on future patents while maintaining strict temperature control for the delivery of its developments. High-liquid assets per share demonstrate capital dynamics, where 6.24 represents the current metric level. However, early molecule tests create risks of loss, which are offset by the existing cash reserve.

CTNM Contineum Corp: Cash Funds per Share in the range 04/06/2024 - 11/20/2026

Comprehensive metric breakdowns and analytics for Contineum Therapeutics Inc (CTNM)

- market price and analyst price targets:
- cash and cash flow data:
Comprehensive company analysis:Contineum Pharma CTNM
Finished products of Contineum Therapeutics

Contineum Therapeutics, Inc. (CTNM) invests in neurological developments and strict adherence to ESG environmental standards during laboratory modernization. This metric reflects the amount of available capital per share, allowing investors to assess financial stability and the risk of business degradation, which is clearly evidenced by the price action of liquid assets per share.